All In Biotech

Drug Trial Radar · NCT06322628

A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of VSA006 Injection in Chinese Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Actual

Start

Apr 22, 2024

Primary completion

Jul 2026

Study completion Jan 2027

Sponsor

Sponsor type
Industry
First posted
Mar 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Human genetic studies have shown that loss of function (LOF) mutations in HSD17β13 gene have a protective effect on the progression of alcohol-related and non-alcohol-related liver diseases, such as NASH, without significant adverse phenotypes. VSA006 is a siRNA drug targeting HSD17β13 mRNA in the liver and reduce the protein level of HSD17β13. Based on phase 1 study results in healthy volunteers and NASH/suspected NASH patients, this phase 2 study is designed to evaluate the efficacy, safety, PK profiles and immunogenicity of VSA006 in Chinese NASH patients.

Conditions

  • Nash

Interventions

  • VSA006Drug

    every 12 weeks, subcutaneous injections

  • PlaceboDrug

    every 12 weeks, subcutaneous injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving ≥ 1 Stage Improvement in Histological Fibrosis with no Worsening of NASHTime frame: At week 52
  2. Percentage of Participants Achieving NASH Improvement with no Worsening of FibrosisTime frame: At week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Changgeng Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.